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Abstract
The major breast cancer suppressor proteins BRCA1 and BRCA2 play essential roles in 
homologous recombination (HR)-mediated DNA repair, which is thought to be critical for tumor 
suppression. The two BRCA proteins are linked by a third tumor suppressor, PALB2, in the HR 
pathway. While truncating mutations in these genes are generally pathogenic, interpretations of 
missense variants remains a challenge. To date, patient-derived missense variants that disrupt 
PALB2 binding have been identified in BRCA1 and BRCA2; however, there has not been 
sufficient evidence to prove their pathogenicity in humans, and no variants in PALB2 that disrupt 
either its BRCA1 or BRCA2 binding have been reported. Here, we report on the identification of a 
novel PALB2 variant, c.104T>C [p.L35P], that segregated in a family with a strong history of 
breast cancer. Functional analyses showed that L35P abrogates the PALB2-BRCA1 interaction and 
completely disables its abilities to promote HR and confer resistance to platinum salts and PARP 
inhibitors. Whole-exome sequencing of a breast cancer from a c.104T>C carrier revealed a 
second, somatic, truncating mutation affecting PALB2, and the tumor displays hallmark genomic 
features of tumors with BRCA mutations and HR defects, cementing the pathogenicity of L35P. 
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Parallel analyses of other germline variants in the PALB2 N-terminal BRCA1-binding domain 
identified multiple variants that affect HR function to varying degrees, suggesting their possible 
contribution to cancer development. Our findings establish L35P as the first pathogenic missense 
mutation in PALB2 and directly demonstrate the requirement of the PALB2-BRCA1 interaction 
for breast cancer suppression.
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Introduction
The BRCA1 and BRCA2 tumor suppressor proteins play critical roles in the repair of DNA 
double strand breaks (DSBs) by homologous recombination (HR), which is generally 
believed to be essential for their tumor suppressive function. The two BRCA proteins are 
linked in the HR pathway by a third tumor suppressor protein, PALB2, via direct protein-
protein interactions.1–4 Similar to BRCA1 and BRCA2, mono-allelic mutations in PALB2 
increase the risk of breast, ovarian and pancreatic cancers,5, 6 whereas bi-allelic mutations 
cause Fanconi anemia (FA).5 In a way akin to the risk conferred by BRCA2 germline 
mutations, in women under 40 years of age, the risk of breast cancer development conferred 
by PALB2 mutations is 8–9 times that of controls and in women older than 60, the risk is 5 
times that of controls.7
PALB2 and BRCA2 interact with each other via a WD40-repeat domain at the C-terminus of 
PALB2, which forms a 7-bladed β-propeller structure, and a highly conserved motif in the 
N-terminus of BRCA2 (aa 21–39) that forms an α-helix.8 The PALB2-BRCA1 interaction, 
on the other hand, is mediated by what appears to be a hydrophobic interaction between a 
conserved coiled-coil motif at the N-terminus of PALB2 (aa 9–42) and a similar motif in 
BRCA1 (aa 1393–1424).1–3 Interestingly, the N-terminus of PALB2 has also been reported 
to mediate its own dimerization or oligomerization,9, 10 suggesting a possible competition 
between the PALB2-PALB2 self-interaction and the PALB2-BRCA1 complex formation.
Numerous sequence alterations in PALB2 have been identified in germline genetic testing of 
familial breast and pancreatic cancers and in tumor DNA sequencing. Based on available 
data as of 2014, the frequency of PALB2 truncating mutations is estimated to be ~2.4% in 
patients with family history of breast cancer worldwide.7 In the United States, a study found 
the rate of truncating mutations to be 3.4% in 972 families without BRCA1/2 mutations but 
unselected for ancestry.11 To date, at least 339 unique sequence variants in PALB2 have 
been found in diverse populations (http://databases.lovd.nl/shared/variants/PALB2/unique), 
with ~100 being protein-truncating and the rest being mostly missense variants of unknown 
significance (VUSs). The crystal structure of the PALB2 C-terminal WD domain, combined 
with results from FA patient-derived cells, has shown that deletion of just 4 amino acids 
from the C-terminus of PALB2 would result in a collapse of the β-propeller structure and 
degradation of the protein.8, 12 Also, premature termination of translation often leads to 
mRNA degradation by nonsense-mediated decay (NMD). As such, practically all PALB2 
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truncating mutations can be considered deleterious and pathogenic. The interpretation of 
VUSs, however, requires detailed functional and genetic analyses. In this regard, the vast 
majority of PALB2 VUSs have not been characterized at all and the associated risks remain 
undetermined for all PALB2 VUSs.
Results
A breast cancer family carrying the c.104T>C [p.L35P] variant in PALB2
The unaffected proband reported a maternal family history of breast cancer (Figure 1a). Her 
mother was diagnosed with invasive breast cancer of the right breast at the age of 33; she 
was treated by a total mastectomy and chemotherapy and later died of an unrelated cause at 
41 years. In the previous generation (II), the maternal grandmother was diagnosed cancer of 
the left breast at 70 and non-Hodgkin’s Lymphoma at 71. The breast cancer was found to be 
estrogen receptor (ER) positive, progesterone receptor (PR) negative and HER2 negative. 
The patient underwent total mastectomy and showed excellent response to subsequent 
letrozole treatment. The patient is presently 78 years old. Her mother was reportedly 
diagnosed with bilateral breast cancer, at the ages of 62 and 68. Clinical testing of germline 
samples from the proband revealed a VUS in the PALB2 gene: c.104T>C [p.L35P] 
(confirmed by Sanger sequencing, Figure 1b, upper trace). The same variant was discovered 
in germline and somatic (tumor) samples from the grandmother, confirming that the 
proband’s mother is an obligate heterozygote for this mutation. No tissue was available for 
the mother. To determine whether the tumor of the maternal grandmother of the proband, 
diagnosed with invasive ductal breast cancer at age 70 years, had undergone loss of 
heterozygosity (LOH) at PALB2, DNA was extracted from macrodissected tumor and 
subjected to PCR-sequencing analysis. Both wild-type (wt) and mutant allele were present in 
the tumor cells and the ratio appears to be 1:1, similar to that in the germline/blood DNA 
(Figure 1b, lower trace), indicating a lack of LOH.
Whole exome sequencing of germline and tumor DNA from a c.104T>C PALB2 carrier
To gain a better understanding of the pathogenicity and somatic mutation pattern associated 
with the L35P variant, blood and tumor DNA from the proband’s maternal grandmother 
were analyzed by whole-exome sequencing (WES) (Supplemental Table 1). L35P was found 
to be present in 45% and 48% of DNA from normal (blood) and tumor tissues, respectively 
(Figure 1c and Supplemental Table 2), confirming the lack of LOH. A clonal somatic 
nonsense mutation affecting the PALB2 gene (Q61*) was identified, providing a mechanism 
for PALB2 bi-allelic inactivation, and suggesting that PALB2 is likely dysfunctional in this 
cancer. Additionally, WES identified 230 somatic mutations in the tumor, of which 175 were 
non-synonymous mutations, some of which affected known cancer genes including ARID1A 
(G794E), CDK12 (P670S) and BCOR (T581N) (Figure 1d–e). The tumor displayed a 
complex genome, with numerous low-level copy number gains and losses, and a focal 
amplification on 8q22. Consistent with the notion that PALB2 is inactivated and that this 
tumor would lack competent HR DNA repair, WES analysis revealed a high score of 27 for 
large-scale state transitions13 (LST, Figure 1e and Supplemental Table 1) and a mutational 
Signature 314 (Figure 1f), both hallmark features of tumors with BRCA1 or BRCA2 
mutations and HR deficiency (HRD).13 Both features have been further confirmed by our re-
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analysis of i) breast cancers harboring BRCA1 germline mutations regardless of ER and 
HER2 status, ii) breast cancers harboring BRCA2 germline mutations regardless of ER and 
HER2 status, and iii) ER-positive (ER+) and HER2-negative (HER2−) breast cancers 
lacking BRCA1 or BRCA2 germline mutations from The Cancer Genome Atlas (TCGA) 
(Supplemental Figure 1). The L35P tumor showed positive nuclear staining for BRCA1 as 
analyzed by immunohistochemistry (IHC) (Supplemental Figure 2), ruling out the 
possibility of its HRD phenotype being due to silencing of BRCA1 expression.
VUSs in the coiled-coil motif of PALB2
Based on the results of the WES analysis, we posited that the PALB2 c.104T>C, p.L35P 
mutation would result in a dysfunctional PALB2 protein unable to elicit HR and DNA repair. 
Interestingly, the affected residue is located in PALB2’s N-terminal coiled-coil motif, the 
binding site for BRCA1.1–3 Notably, in the coiled-coil motif there are at least 4 other VUSs 
(K18R, Y28C, K30N and R37H) previously identified in the germline samples of patients 
with familial breast cancer (Figure 2a and Table 1). Among them, Y28C was originally 
discovered in a male breast cancer patient in a family with both female and male breast 
cancers.15 K18R is also notable as it has been found 18 times in 5 different studies (Table 1). 
All affected residues are highly conserved in vertebrates. Based on a previously proposed 
PALB2-BRCA1 interaction model,2 Y28 and L35 are both located at the predicted 
hydrophobic interaction interface, whereas K18, K30 and R37H are placed away from the 
interface (Figure 2b). As such, only Y28C and L35P are expected to affect BRCA1 binding. 
It should be noted, however, that the model remains speculative due to the lack of crystal or 
nuclear magnetic resonance (NMR) structural information.
Effect of the PALB2 variants on BRCA1 binding and HR function
To determine the functional impact of the above VUSs, we first tested their abilities to 
interact with BRCA1 by immunoprecipitation (IP). Y28C and L35P both abrogated the co-
IP of the endogenous BRCA1 with the ectopically expressed PALB2 proteins in 293T cells, 
whereas K18R, K30N and R37H did not significantly affect the complex formation (Figure 
2c and data not shown). Interactions of the PALB2 variants with BRCA2 and RAD51 were 
all unaffected, consistent with the fact that BRCA2 binds to the C terminus of PALB2.8, 10 
We next asked if any of these variants would disrupt PALB2 HR function, by testing their 
ability to rescue HR following the depletion of the endogenous PALB2 in U2OS/DR-GFP 
reporter cells.4 Surprisingly, all of the variants but K30N caused varying degrees of 
reduction in HR ability (Figure 2d). Consistent with the genomics observations made in the 
WES analysis of the L35P PALB2 mutant breast cancer, the L35P mutation completely 
abrogated the HR activity of PALB2. Although PALB2-Y28C behaved similarly to PALB2-
L35P in the co-IP assay, it retained ~35% of HR activity of the wt protein. These results 
suggest that the variants may affect the integrity of the coiled-coil motif and that even a 
modest distortion of the structure could result in reduced HR activity, even if the binding of 
BRCA1 is not affected.
Effects of the variants on PALB2 dimer/oligomerization
In addition to binding BRCA1, the N-terminus of PALB2 also mediates its own dimerization 
or oligomerization.9, 10 Deletion of the N-terminus results in dissociation of PALB2 dimer/
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oligomers, higher DNA binding affinity and increased activity in promoting RAD51 
nucleoprotein filament formation and strand invasion in vitro.9 Nonetheless, due to the fact 
that deletion of the N terminus also abolishes BRCA1 binding, which is critical for PALB2 
recruitment to DNA damage sites, the in vivo relevance of PALB2 dimer/oligomer formation 
has been difficult to assess. To determine the effect of the variants on dimer/oligomer 
formation, we introduced the sequence alterations in a “mini-PALB2” that lacks the 
sequence encoded by exon 4.16 Due to the smaller size of the mini-PALB2 (PALB2Δ4) 
proteins, they can be clearly separated from the endogenous PALB2 on a western blot. When 
the proteins were transiently expressed in 293T cells and IPed, a small amount of 
endogenous PALB2 was co-IPed with all of them (Figure 2e and data not shown). Y28C and 
L35P moderately but reproducibly reduced the amount of endogenous PALB2 co-IPed, 
whereas K18R showed no significant effect (Figure 2e). To more directly measure dimer/
oligomer formation, we overexpressed the full-length variant proteins in 293T cells and 
subjected the lysates to gel filtration. L35P showed no discernible effect on the elusion 
profile of the overexpressed PALB2 (largely free of binding proteins due to overexpression), 
while Y28C caused a very slight shift of the PALB2 peak to the right (smaller molecular 
weight) (Fig. 2f). As a positive control, deletion of the coiled-coil motif caused a clear shift 
to the right, indicative of a compromised self-interaction. Taken together, these data suggest 
that Y28C and L35P may weaken but do not disrupt PALB2 self-interaction. Note that 
PALB2 appears to form both dimers and oligomers, but the exact mode and in vivo function 
of PALB2 self-interaction remains unknown.
L35P abrogates PALB2 and RAD51 recruitment to DNA damage sites
We next sought to characterize in greater detail the basis of the HR repair deficiency caused 
by the VUSs, except PALB2-K30N, which was completely functional in HR (Figure 2d). 
EUFA1341 cell lines stably expressing each of these variant PALB2 proteins were 
generated. EUFA1341 is a SV40-transformed skin fibroblast cell line derived from an FA-N 
patient with biallelic mutations in PALB2, a nonsense mutation (c.1802T>A, p.Y551*) on 
one allele and a loss of the other allele due to a genomic deletion, which result in the 
expression of a truncated PALB2 protein lacking the ability to bind BRCA2 and recruit 
BRCA2-RAD51 following DNA damage.16 As we and others have shown that BRCA1 
promotes the recruitment of PALB2 to DSBs,1–3 the ability of the PALB2 variants to form 
ionizing radiation-induced foci (IRIF) was determined. As depicted in Figure 3a, wt PALB2 
forms IRIF that largely co-localize with those of BRCA1, and PALB2-K18R and R37H 
behaved similarly to the wt protein. The Y28C variant was also able to form IRIF, but the 
foci were fewer, suggesting that its recruitment is partially impaired. In contrast, PALB2-
L35P failed to form any foci, indicative of a completely abrogated recruitment. Consistent 
with our previous observations,16 EUFA1341 cells were completely defective in RAD51 
IRIF formation, and the defect was fully restored upon re-expression of wt PALB2 (Figure 
3b). Again, PALB2-L35P was completely unable to support RAD51 foci formation, and 
Y28C appeared to be hypomorphic as the protein was able to support RAD51 foci formation 
but the foci were evidently smaller and also modestly fewer in number (Fig. 3c). Normal 
RAD51 foci formation was observed in cells expressing PALB2-K18R and R37H (data not 
shown). These observations demonstrate the important role of BRCA1 for PALB2 
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recruitment and the requirement of PALB2 for RAD51 foci formation. The expression levels 
of wt and variant proteins were largely comparable (Figure 3d).
PALB2-L35P is unable to confer resistance to DNA damaging agents
Defects in HR-mediated repair have been shown be predictive of clinical response to 
commonly used platinum drugs among breast and ovarian cancer patients17, 18. Similarly, we 
have shown that PALB2-deficient cells are hypersensitive to mitomycin C (MMC) and the 
poly (ADP-ribose) polymerase (PARP) inhibitor olaparib.16, 19 Therefore, we assessed the 
sensitivity of EUFA1341 cells expressing the different variants to these DNA damaging 
agents. As expected, while re-expression of wt PALB2 in EUFA1341 cells conferred 
resistance to all three types of drugs, cells expressing PALB2-L35P were indistinguishable 
from vector-harboring cells (Figure 3e). Cells expressing other variant proteins showed 
resistance to all 3 types of drugs, although there were modest differences in their sensitivities 
to olaparib and MMC. Surprisingly, despite its substantially reduced HR activity as 
measured by the DR-GFP reporter assay (Figure 2d), PALB2-Y28C conferred a wild-type 
level of resistance to both cisplatin and MMC and nearly wild-type level of resistance to 
olaparib (Figure 3e), suggesting that the residual HR activity was sufficient to confer 
resistance to the drugs.
Discussion
VUSs are commonly found during clinical genetics tests but their clinical and biological 
significance is often difficult to define, and this uncertainty poses significant challenges for 
clinicians and patients. Although our understanding of how cancers develop following the 
loss of BRCA1/2 and PALB2 remains far from complete, it is generally accepted that the 
resulting DNA repair defect and ensuing genome instability are a root cause. Moreover, the 
HR defect of BRCA/PALB2 mutant tumor cells is now being rationally targeted by DNA 
damaging agents that generate lesions that require HR for repair, such as platinum salts and 
PARP inhibitors.20, 21 Therefore, functional assessment of DNA repair properties of VUSs is 
required for the understanding of their pathogenicity, and this information is germane to 
treatment decision-making, risk prediction and management of both patients and family 
members.
PALB2 directly interacts with both BRCA1 and BRCA2 and acts as essential linker between 
the two proteins in the HR pathway.1–3 While patient-derived missense mutations that 
disrupt PALB2 binding have been identified in both BRCA1 and BRCA2,2, 4 there has been 
limited evidence that confirm their pathogenicity in humans, and no such mutations in 
PALB2 have been reported to date. Here, we identify a novel missense variant, L35P, in the 
coiled-coil motif of PALB2 that mediates BRCA1 binding. We establish that L35P is a bona 
fide null mutation that disrupts BRCA1 binding and completely abrogates the HR activity of 
PALB2 and its ability to confer resistance to DNA damaging agents. Whole-exome 
sequencing analysis of a breast cancer from a L35P germline mutation carrier provides 
direct evidence of bi-allelic inactivation of PALB2 through a second, somatic, truncating 
mutation in the gene. Moreover, the tumor displays genomic features of breast cancers with 
HR DNA repair defects, including complex patterns of copy number alterations, the 
Foo et al. Page 6













Signature 314 and a high large-scale state transitions score.13 Thus, L35P is a pathogenic 
mutation, and tumors from L35P mutation carriers are likely to respond to agents that target 
HR DNA repair defects, such as olarparib, cisplatin and MMC, provided that the wt allele of 
PALB2 is deleted, mutated or epigenetically silenced.
Interestingly, the HR function of PALB2 is also affected by multiple other VUSs in the 
coiled-coil motif, particularly Y28C, which causes a 65% reduction of HR activity (Figure 
2d). Although Y28C affects the PALB2-BRCA1 co-IP to a similar extent to L35P (Figure 
2c), it can still be recruited to BRCA1-containing foci when stably expressed in EUFA1341 
cells, albeit with moderately reduced efficiency (Figure 3a). This suggests that Y28C may in 
fact reduce the stability of the PALB2-BRCA1 complex to a point where the complex can no 
longer withstand the cell lysis or IP conditions used, rather than disrupting the complex 
formation altogether. The substantially reduced HR activity of PALB2-Y28C suggests that 
the foci are less productive, potentially due to imprecise location or suboptimal 
configuration. This scenario is supported by the observation that the RAD51 foci in 
EUFA1341 cells expressing PALB2-Y28C are noticeably smaller (Figure 3c,d). Yet, these 
cells are fully resistant to cisplatin and MMC with only a slight sensitivity to olaparib 
(Figure 3e), indicating that the residual HR activity is largely sufficient to confer drug 
resistance under the setting used. To our surprise, K18R and R37H also impair the HR 
activity of PALB2 even though they do not appear to reduce the PALB2-BRCA1 interaction 
(Figure 3b). One potential explanation is that they may affect higher order structures of the 
PALB2-BRCA1 and PALB2-PALB2 complexes, which could fine-tune HR activity. Similar 
to Y28C, these variants do not cause significant changes in drug sensitivity (Figure 3d). 
Thus, partial HR impairment may not translate into meaningful sensitivity to genotoxic 
therapies. However, variants with intermediate HR defects may well increase cancer risk, as 
recently demonstrated in a mouse model for the BRCA2 G25R variant, which weakens its 
binding to PALB2.4, 22
We have previously reported a Palb2 knockin mouse strain with a mutation in the coiled-coil 
motif (CC6, 24 LKR26 to 24 AAA26).23 The CC6 mutation appears to abrogate the BRCA1-
PALB2 interaction as assessed by co-IP and the HR activity of PALB2 as measured with 
U2OS/DR-GFP cells. The homozygous mutant mice are viable but show a moderate defect 
in spermatogenesis. B cells isolated from the mutant mice are able to form detectable 
RAD51 foci following MMC treatment, but the foci are smaller and dimmer, and the cells 
are hypersensitive to the drug. Human PALB2-Y28C is similar to mouse PALB2-CC6 in that 
it also affects the interaction with BRCA1 and can only support formation of smaller 
RAD51 foci; however, RAD51 foci in EUFA1341 cells expressing the Y28C protein are 
brighter and more distinct than those in the above-mentioned mouse B cells. Moreover, 
PALB2-Y28C retains significant HR activity and, at least when overexpressed, is fully 
capable of conferring resistance to DNA damaging agents. L35P, on the other hand, is a null 
mutation that completely abrogates the ability of PALB2 to support RAD51 foci formation 
and its HR function. Overall, these results together demonstrate the importance of the 
PALB2-BRCA1 interaction for RAD51 foci assembly. At the same time, the results also 
point to the existence of a possible threshold in the size and structure of RAD51 foci for the 
determination of HR activity and drug resistance, as well as a possible difference in the 
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degree of dependence of RAD51 foci assembly on the PALB2-BRCA1 interaction in mouse 
and human cells.
It has been well established that BRCA1 mutant tumors are predominantly triple negative 
and BRCA2 tumors are mostly ER positive. The underlying mechanisms that cause the 
dramatic difference remain poorly understood, although there have been reports that BRCA1 
regulates ER transcription.24 As for PALB2 tumors, recent consensus is that around 70% are 
ER+ and 30% are triple negative.7 Thus, the PALB2 phenotype sits between BRCA1 and 
BRCA2 but is much closer to BRCA2, consistent with the fact that it functions in a stable 
and high stoichiometry complex with BRCA2 while its interaction to BRCA1 is, though 
critical for HR, of much lower stoichiometry or and/stability. In others words, PALB2 has 
considerably more in common with BRCA2 than BRCA1. Moreover, as mentioned above, 
BRCA1 has been reported to play significant roles in transcriptional regulation, which could 
be the key for its triple negative cancer phenotype but completely independent of its role in 
recruiting PALB2 (and therefore BRCA2 and RAD51) to DNA damage sites. These could 
explain the ER+ phenotype of the L35P tumor studies here. Although patient-derived 
BRCA1 missense variants that disrupt PALB2 binding have been identified2, there have not 
been any reports on the phenotypes of those BRCA1 tumors. It would be interesting to know 
if the tumors will be triple negative like most BRCA1 null tumors or instead ER+ similar to 
what was observed in the L35P tumor.
In summary, we have now identified a novel PALB2 variant, c.104T>C [p.L35P], which 
segregates in a family with a strong history of breast cancer. Our results from WES and 
functional analyses established L35P as the first bona fide null and pathogenic missense 
mutation in PALB2. These results for the first time directly demonstrate the requirement of 
the BRCA1-PALB2 interaction for breast cancer suppression. Our expanded analyses of 
other germline VUSs in the coiled-coil motif showed a certain VUS, such as Y28C, can 
significantly affect HR activity but have little or no effect on drug resistance, suggesting that 
a mutation may increase cancer risk but may not predict therapy response. The present study 
and our above-noted mouse study corroborate with each other to demonstrate the importance 
of the PALB2-BRCA1 interaction in RAD51 foci formation and drug resistance, as well as 
in male fertility and suppression of cancer development.
Materials and methods
Patients and genotyping
The proband attended the Hereditary Cancer Clinic at the Jewish General Hospital, 
Montreal, QC, Canada, on account of her strong family history of breast cancer. Chart notes 
confirmed her mother’s diagnosis, and pathology reports and personal report confirmed her 
maternal grandmother’s diagnosis. Blood was sent from the proband to Invitae (San 
Francisco, CA) where massively parallel sequencing of BRCA1, BRCA2, CHEK2, PALB2 
and TP53 was performed. c.104T>C in PALB2 was the only variant called by Invitae, and it 
was categorized as a VUS. We obtained both saliva and formalin-fixed, paraffin-embedded 
(FFPE) breast tumor tissue from the maternal grandmother. Sequencing of the lymphocyte 
and tumor-derived DNA, was carried out as previously described.25 The study was approved 
by the Institutional Review Board of the Faculty of Medicine of McGill University, 
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Montreal, QC, Canada, no. A12-M117–11A. Informed consent was obtained from all 
subjects.
Whole-exome sequencing
Extracted DNA samples from the microdissected tumor and the matched germline DNA 
extracted from peripheral blood were subjected to whole exome capture using the SureSelect 
Human All Exon v4 (Agilent) capture system and to massively parallel sequencing on an 
HiSeq 2000 at the Memorial Sloan Kettering Cancer Center Integrated Genomics Operation 
(IGO) following validated protocols.26, 27 Whole-exome sequencing analysis was performed 
as described previously28. The coverage was 202.21x for the tumor sample and 77.52x for 
the normal sample.
Paired-end reads in FASTQ format were aligned to the reference human genome GRCh37 
using Burrows-Wheeler Aligner (BWA, v0.7.5a) 29. Local realignment and base quality 
adjustment was performed using the Genome Analysis Toolkit (GATK, v2.7.4) 30. Somatic 
single nucleotide variants (SNVs) were identified using MuTect (v1.0) 31 Small insertions 
and deletions (indels) were detected using Strelka (v2.0.15)32 and VarScan 2 (v2.3.7).33 
Mutations were filtered as previously described 28. Copy number alterations (CNAs) were 
identified using FACETS 34, which performs a joint segmentation of the total and allelic 
copy ratio and infers allele-specific copy number states, as previously described.35 The 
cancer cell fraction (CCF) of each mutation was inferred using the number of reads 
supporting the reference and the alternate alleles and the segmented Log2 ratio from MPS as 
input for ABSOLUTE (v1.0.6).36 Solutions from ABSOLUTE were manually reviewed as 
recommended 36, 37. A mutation was classified as clonal if its clonal probability, as defined 
by ABSOLUTE, was >50%37 or if the lower bound of the 95% confidence interval of its 
CCF was >90%. Mutations that did not meet the above criteria were considered subclonal. 
Mutations were annotated using a combination of driver prediction methods, Mutation 
Taster,38 CHASM (breast)39 and FATHMM,40 and presence in three cancer gene lists41–43 to 
define the potential functional effect of each non-synonymous SNV.
Circos Plot
A circos plot for case IDC53 was produced by binning all variants of high confidence 
(curation methodology described previously), into one of four categories “frameshift in-del,” 
“truncating SNV,” “missense SNV,” “inframe in-del,” “splice site variant,” “upstream, start/
stop, or de novo modification,” or “silent” according to the functional salience of each 
aberrant locus, after which silent variants were discarded. Remaining variants were 
subsequently annotated if present in one of three reference sets diagnostic of potential 
pathogenicity as described above. Copy number assignments made using the FACETS 
algorithm 34 and post-processed (as described above) to determine per-gene allelic status as 
either “deleted,” “lost,” “neutral,” “gained,” or “amplified,” were then mapped to 
correspondent segmentation data. The annotated variant and copy number information were 
then displayed using the OmicCircos software package 44 with respect to genomic position 
using the hg19 reference.
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To define mutational signatures in tumors, we measured the mutational context of all 
synonymous and non-synonymous somatic SNVs within the target regions. For each tumor 
component, we extracted the 5′ and 3′ sequence context of each mutation from the 
GRCh37 reference genome and the SNVs were categorized into C>A, C>G, C>T, T>A, 
T>C and T>G bins according to the type of substitution and subcategorized them according 
to the nucleotides preceding (5′) and succeeding (3′) the mutated base. The number of 
SNVs for each of the 96 sub-bins representing the tri-nucleotides [A|C|G|T] [C>A|C>G|C>T|
T>A|T>C|T>G] [A|C|G|T] were counted.
The proportion of mutations belonging to the 96 sub-bins were normalized using the 
observed trinucleotide frequency in the target regions of the respective sequencing platforms 
to that in the human genome as previously described.45, 46 The normalized mutational 
patterns were compared to the mutation signatures using non-negative least squares, such 
that a linear combination of the mutation signatures that is equal to the mutation pattern was 
found. The mutation signature of the tumor analyzed here was defined as the mutation 
signature with the highest coefficient.
Large-scale state transitions (LSTs)
Using previously established classification guidelines,13 LSTs were defined as chromosomal 
breaks (i.e., changes in copy number of major allele counts) between adjacent regions of at 
least 10Mb. LSTs were quantified after smoothing and filtering small-scale copy number 
variations (<3Mb). The tumor had an LST score of ≥15, which was categorized as high (i.e. 
associated with HR DNA repair defects, according to the original report describing LSTs.13
Re-analysis of The Cancer Genome Atlas (TCGA) breast cancer samples
To define the LST scores and mutational signatures of i) breast cancers harboring BRCA1 
germline mutations regardless of ER and HER2 status, ii) breast cancers harboring BRCA2 
germline mutations regardless of ER and HER2 status, and iii) ER-positive (ER+) and 
HER2-negative (HER2−) breast cancers lacking BRCA1 or BRCA2 germline mutations, we 
retrieved the MAF file of the breast cancers analyzed by TCGA47 from the Broad Firehose 
portal (http://gdac.broadinstitute.org/), and the Affymetrix SNP6 array data for tumor and 
normal samples from the TCGA Data portal (https://tcga-data.nci.nih.gov/tcga/) on 1/28/15. 
Affymetrix SNP6 array data were used to determine LST scores for each TCGA sample as 
described above. Whole-exome sequencing data were employed to define the mutational 
signatures as described above.
Cell lines and cultures
U2OS/DR-GFP HR reporter cells and SV40-transformed EUFA1341 fibroblasts were 
previously described.4, 16 EUFA1341 cell lines reconstituted with wt or variant PALB2 
proteins were generated as previously described.16 These and 293T cells were all cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum 
and 1X Penicillin-Streptomycin (Pen-Strep), at 37°C in a humidified incubator with 5% 
CO2.
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PALB2 proteins were expressed using the pOZ-FH-C1-PALB2 retroviral vector as 
previously described.23 Site-directed mutagenesis was performed according to the 
QuikChange protocol (Agilent Technologies). DNA transfections were carried out using X-
tremeGENE 9 or X-tremeGENE HP (Roche).
Homologous recombination assay
HR activity of various PALB2 proteins was determined using the U2OS/DR-GFP reporter 
cells as described before.23 In short, the endogenous PALB2 protein was first depleted using 
an siRNA (5′-UCAUUUGGAUGUCAAGAAAdTdT-3′) for 30 hr. Cells were then reseeded 
into 6-well plates and after overnight adaptation co-transfected with an I-SceI expression 
vector and the siRNA resistant pOZ-FH-C1-PALB2 constructs. GFP-positive cells were 
scored by flow cytometry 48–54 hr after the second transfection.
Immunoprecipitation (IP) and western blotting
The whole procedure was performed essentially as previously described 23. In brief, cDNA 
constructs were transfected into 293T cells in 6-well plates using X-tremeGENE HP. Cell 
lysates were prepared ~30 hr post-transfection using a NETNG-250 lysis buffer (250 mM 
NaCl, 1 mM EDTA, 20 mM Tris-HCl, 0.5% Nonidet P-40, and 10% glycerol) containing 
Complete® protease inhibitor mixture (Roche). The FLAG-HA-tagged PALB2 were IPed 
with anti-FLAG M2-agarose beads (Sigma). Proteins were resolved on 4–12% Tris-glycine 
gels and analyzed by immunoblotting. The PALB2 antibody used (M11, against aa 601–880) 
was described before.4, 23 Other antibodies used include polyclonal BRCA1 antibody 
(07-434, EMD Milipore), BRCA2 (OP95, EMD Milipore), RAD51 (H-92, Santa Cruz) and 
GAPDH (FL-335, Santa Cruz).
Gel filtration
PALB2 proteins tagged with FLAG-HA epitopes at the C terminus were overexpressed in 
293T cells by transient transfection. Cells were collected 30 hr after transfection and lysed in 
NETNG250 (250 mM NaCl, 1mM EDTA, 20mM Tris-HCl, 0.5% Non-Idet P-40, 10% 
glycerol) with 5 mM NaF. Insoluble material was removed by high speed centrifugation 
(16,000 rpm for 30 min) at 4°C. 2 mg of each extract was analyzed on an FPLC AKTA 
Purifier (GE Healthcare) with a Superpose 6, 10/300 GL Tricorn column pre-equilibrated 
with NETNG250 (with 0.2% Non-Idet P-40) buffer containing 5mM NaF. 0.6 ml fractions 
were collected, and the proteins in the fractions were analyzed by western blotting using 
anti-PALB2.
Immunofluorescence
Cells were seeded onto coverslips in 12-well plates at a density of 150,000 cells per well the 
day before analysis. Following 10 Gy of IR and 6 hr recovery, cells were washed with PBS 
and fixed with 3% paraformaldehyde/PBS for 6 min at room temperature (RT). For staining, 
cells were permeabilized with 0.5% triton X-100 for 5 min on ice and then incubated 
sequentially with primary and secondary antibodies for 30 min each at 37°C, with 3 PBS 
washes in between. The primary antibodies used were PALB2 (M11), RAD51 (H-92) and 
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BRCA1 (D9, Santa Cruz), and the secondary antibodies were FITC-conjugated goat anti-
rabbit and Rhodamine-conjugated goat anti-mouse antibodies (Jackson ImmunoResearch). 
Coverslips were mounted onto glass slides with VECTASHIELD Mounting Medium with 
DAPI (Vector Labs). Images were captured using a Nikon Eclipse TE-2000-U microscope. 
Images of the same group were captured with identical exposure time using NIS-Elements 
Basic Research software.
Drug sensitivity assay
EUFA1341 cells were seeded at 2,000 cells per well in 96-well plates. The day after seeding, 
drug compounds were first diluted in the medium and then added to the wells to achieve the 
desired final concentrations. Cells were incubated with the drugs for 96 hr and survival rates 
were measured using CellTiterGlo Cell Viability Assay (Promega) according to 
manufacturer’s instructions.
Statistical analysis
Statistical significance was analyzed by either two-tailed, paired Student’s t-test or one way 
ANOVA using GraphPad Prism 5.0 (GraphPad Software). P values of less than 0.05 were 
considered statistically significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Characterization of a breast cancer from a family carrying the PALB2 c.104T>C [p.L35P] 
variant. (a) Pedigree of the family. The proband is marked by a filled triangle. Confirmed 
mutations carriers are indicated by a “+” sign. Obligate carriers are indicated by a [+] sign. 
Mutation status in all other person is unknown. (b) Presence of the L35P mutation in the 
germline DNA and tumor DNA of the affected grandmother. (c) Presence of the L35P and 
Q61* mutations in normal (blood) and tumor DNAs of the affected grandmother. (d) Circos 
plot depicting the mutations and copy number alterations across the genome. Mutations are 
shown along the outside, including annotations on cancer gene status and mutation type 
(color-coded according to the legend), with the chromosomal position arranged along the 
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middle ring. The 96 substitution classifications defined by the substitution classes are 
shown, and clonal mutations are indicated with a golden mark. Copy number alterations are 
depicted along the center ring color-coded according to the legend. (e) Diagram depicting 
the somatic mutations identified affecting cancer genes. The LST status (top), mutation 
types (left) and cancer cell fractions (right) are shown, color-coded according to the legend. 
(f) Mutational signature of all somatic synonymous and non-synonymous SNVs identified. 
Variants are displayed according to the 96 substitution classification and the 5′ and 3′ 
sequence context, normalized to the trinucleotide frequency of the human genome. Indel, 
small insertion and deletion; LOH, loss of heterozygosity; LST, large-scale state transition; 
SNV, single nucleotide variant.
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Effects of PALB2 N-terminal VUSs on BRCA1 binding, HR activity and PALB2 self-
interaction. (a) Amino acid sequence alignment of the PALB2 N terminus. The alignment as 
generated by ClustalW. The VUSs studied are marked on top. (b) Predicted model of the 
interaction between the coiled-coil motifs of PALB2 and BRCA1. Hydrophobic residues at 
the interface are shown. Residues affected by VUSs are shown in red. (c) Effects of the 
PALB2 variants on BRCA1 and BRCA2 binding. The proteins were transiently expressed in 
293T cells and IPed with anti-FLAG M2 beads. The amounts of relevant proteins in the 
input whole cell lysate (WCL) and IPed materials were determined by western blotting. (d) 
Effects of the variants on the HR activity of PALB2. U2OS/DR-GFP cells were first 
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depleted of the endogenous PALB2 by an siRNA and then rescued with the wt and variant 
PALB2 proteins by transient transfection. Error bars represent standard deviations (SDs) 
from at least three independent experiments. Statistical significance was analyzed by one 
way ANOVA and Newman-Keuls post hoc analysis. ***, p<0.001; ns, not significant. (e–f) 
Effects of the variants on PALB2 self-interaction. The variants were introduced into 
PALB2Δ4 and the binding between these shortened PALB2 proteins and the endogenous 
PALB2 were assessed by IP-western following transient transfection into 293T cells (e). 
FLAG-HA-tagged full-length PALB2 variant proteins were transiently overexpressed in 
293T cells and analyzed by gel filtration followed by western blotting using anti-PALB2. 
Fraction numbers are marked above the blots and the approximate corresponding molecular 
weights of the fractions below.
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Effects of PALB2 N-terminal VUSs on PALB2 and RAD51 foci formation and cellular 
sensitivity to DNA damaging agents. (a–b) PALB2 and RAD51 IRIF formation in 
EUFA1341 stable cell lines. Cells were treated with 10 Gy of IR, fixed after 6 hr recovery 
and analyzed by immunofluorescence using PALB2 (a) and RAD51 (b) antibodies, 
respectively. BRCA1 was co-stained with each of PALB2 and RDA51 to indicate sites of 
DNA damage and level of co-localization. (c) Efficiency and size of RAD51 foci formation 
in the above stable cell lines. Left, the percentage of RAD51 foci positive cells among 
BRCA1 foci positive (S and G2 phase) cells; right, sizes of the RAD51 foci in EUFA1341 
cells expressing wt PALB2 and PALB2-Y28C. Error bars represent standard deviations 
(SDs) from 3 independent experiments. Statistical significance was calculated with Student’s 
t-test. *, p<0.05; ***, p<0.001. (d) Representative western blots showing the levels of 
PALB2 and BRCA1 in the EUFA1341 stable cell lines. GAPDH was used a loading control. 
(e) Sensitivities of the EUFA1341 stable cell lines to cisplatin, olaparib and MMC. Cells 
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were incubated with the drugs for 96 hr. Data presented are the means of at least 3 
independent experiments. Error bars represent standard deviations.
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Table 1
Overview of the 5 PALB2 N-terminal VUSs examined in this study. POLYPHEN/SIFT predictions were made 
at the time of original reports. See LOVD PALB2 mutation database (http://databases.lovd.nl/shared/variants/
PALB2/unique) for further details.
cDNA mutation Amino acid change POLYPHEN/SIFT prediction Description Reference
c.53A>G K18R Probably damaging/tolerated mutation Reported 19 times in 5 independent 
studies
1 Identified in 1 out of 95 in 
probands from families 
with cases of early onset 
prostate cancer (age at 
diagnosis <55 years) 
enrolled at University of 
Michigan Prostate Cancer 
Genetics Project (PCGP).
2 Identified in 3 out of 139 
early-onset African-
American breast cancer 
cases recruited at Parkland 
Hospital, affiliated with 
the University of Texas 
Southwestern Medical 
Center.
3 Identified in 3 out of 158 
German patients with 
bilateral breast cancers.
4 Identified in 11 out of 
1240 successfully 
sequenced probands 
enrolled through USA 
familial cancer clinics by 
the Breast Cancer Family 
Registry.
5 Identified in 1 out of 279 
African American women 
with breast cancer 
recruited at the Cancer 
Risk Clinic at the 
University of Chicago.
48–52
c.83A>G Y28C Probably damaging/alters protein 
function
Single patient identified from study on 
115 male breast cancer patients, with the 
patient diagnosed with breast cancer at 
age 46 and having one first degree and 
two second-degree female relatives 
diagnosed with breast cancer.
15
c.90G>T K30N Probably damaging/alters protein 
function
Identified in 1 out of 747 youngest 
women from multiple-case breast cancer 
families not known to carry a mutation in 
BRCA1 or BRCA2.
53
c.104 T>C L35P Probably damaging/alters protein 
function
Identified in a family of Western 
European descent with strong evidence of 
familial breast cancer.
This study.
c.110G>A R37H Probably damaging/alters protein 
function
Reported in 2 independent studies
1 Identified in 1 out of 132 
non-BRCA1/BRCA2 
Spanish breast/ovarian 
cancer families with at 
least one pancreatic cancer 
case.
54, 55
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cDNA mutation Amino acid change POLYPHEN/SIFT prediction Description Reference
2 Identified in 1 out of 565 
unilateral breast cancer 
patient recruited from 
WECARE study involving 
breast cancer patients from 
USA and Denmark 
diagnosed before age of 
55.
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